
Novartis Kidney Drug Demonstrates Sustained Efficacy in Long-Term Study Data
Novartis's kidney drug Vanrafia shows sustained efficacy in slowing kidney function decline, supporting its path to full regulatory approval in 2026 for IgA nephropathy treatment.
NVSkidney diseaseEGFR